Medexus Pharmaceuticals (TSE:MDP - Get Free Report) had its price target upped by equities researchers at Stifel Nicolaus from C$4.15 to C$4.50 in a research note issued to investors on Tuesday,BayStreet.CA reports. Stifel Nicolaus' price target suggests a potential upside of 0.67% from the stock's previous close.
A number of other analysts have also weighed in on MDP. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a "strong-buy" rating in a report on Monday, December 23rd. Raymond James upgraded Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 price objective on the stock in a research report on Wednesday, January 8th. Finally, Leede Financial set a C$8.25 target price on Medexus Pharmaceuticals and gave the company a "speculative buy" rating in a report on Monday, September 30th. Two analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Strong Buy" and a consensus target price of C$5.58.
View Our Latest Analysis on MDP
Medexus Pharmaceuticals Trading Up 5.2 %
Shares of TSE:MDP traded up C$0.22 on Tuesday, reaching C$4.47. 97,552 shares of the company traded hands, compared to its average volume of 101,878. The stock has a market capitalization of C$109.65 million, a P/E ratio of 89.40 and a beta of 1.96. The business's 50-day simple moving average is C$2.88 and its 200 day simple moving average is C$2.59. Medexus Pharmaceuticals has a 52 week low of C$1.47 and a 52 week high of C$4.50.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Read More
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
